{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:13:29Z","timestamp":1792534409180,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA217833"],"award-info":[{"award-number":["R01 CA217833"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ymthe.2024.06.006","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T01:44:40Z","timestamp":1717983880000},"page":"2762-2777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy"],"prefix":"10.1016","volume":"32","author":[{"given":"Piyush","family":"Gondaliya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil Ali","family":"Sayyed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene K.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbye","family":"Ziemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7021-9532","authenticated-orcid":false,"given":"Tushar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.06.006_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41573-022-00393-8","article-title":"Author Correction: The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2024.06.006_bib2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ymthe.2024.06.006_bib3","article-title":"PD-L1 inhibitors in the pipeline: Promise and progress","volume":"7","author":"Vanella","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2024.06.006_bib4","article-title":"Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies","volume":"14","author":"Yu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.006_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.trecan.2018.01.007","article-title":"Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma","volume":"4","author":"Hogdall","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ymthe.2024.06.006_bib6","article-title":"High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer","volume":"10","author":"Ahn","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2024.06.006_bib7","article-title":"Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.006_bib8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/CMR.0000000000000260","article-title":"Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res."},{"key":"10.1016\/j.ymthe.2024.06.006_bib9","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2024.06.006_bib10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7150\/thno.35568","article-title":"RNA Nanotechnology-Mediated Cancer Immunotherapy","volume":"10","author":"Lin","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ymthe.2024.06.006_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11427-022-2171-2","article-title":"RNA therapeutics: updates and future potential","volume":"66","author":"Zhang","year":"2023","journal-title":"Sci. China. Life Sci."},{"key":"10.1016\/j.ymthe.2024.06.006_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41392-024-01770-y","article-title":"Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2024.06.006_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10374","article-title":"RNA therapeutics in the clinic","volume":"8","author":"Curreri","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.06.006_bib14","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.06.006_bib15","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1021\/acs.molpharmaceut.1c00669","article-title":"Mesenchymal Stem Cell-Derived Exosomes Loaded with miR-155 Inhibitor Ameliorate Diabetic Wound Healing","volume":"19","author":"Gondaliya","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2024.06.006_bib16","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/jat.3938","article-title":"Safety of bovine milk derived extracellular vesicles used for delivery of RNA therapeutics in zebrafish and mice","volume":"40","author":"Matsuda","year":"2020","journal-title":"J.\u00a0Appl. Toxicol."},{"key":"10.1016\/j.ymthe.2024.06.006_bib17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/hep4.1462","article-title":"Targeting Liver Cancer Stem Cells Using Engineered Biological Nanoparticles for the Treatment of Hepatocellular Cancer","volume":"4","author":"Ishiguro","year":"2020","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.ymthe.2024.06.006_bib18","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/jso.21376","article-title":"Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T\u00a0cells as a mechanism of immune evasion","volume":"100","author":"Ye","year":"2009","journal-title":"J.\u00a0Surg. Oncol."},{"key":"10.1016\/j.ymthe.2024.06.006_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1021\/jacs.7b11754","article-title":"Endosomal Escape and Delivery of CRISPR\/Cas9 Genome Editing Machinery Enabled by Nanoscale Zeolitic Imidazolate Framework","volume":"140","author":"Alsaiari","year":"2018","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2024.06.006_bib20","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1021\/acs.molpharmaceut.1c00213","article-title":"MiR-155 Inhibitor-Laden Exosomes Reverse Resistance to Cisplatin in a 3D Tumor Spheroid and Xenograft Model of Oral Cancer","volume":"18","author":"Sayyed","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2024.06.006_bib21","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1038\/s41598-022-09964-6","article-title":"Combination gemcitabine and PD-L1xCD3 bispecific T\u00a0cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells","volume":"12","author":"Wathikthinnakon","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2024.06.006_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102734","article-title":"siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model","volume":"10","author":"Jung","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2024.06.006_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cells9092043","article-title":"Cellular Uptake of siRNA-Loaded Nanocarriers to Knockdown PD-L1: Strategies to Improve T-cell Functions","volume":"9","author":"Thiramanas","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2024.06.006_bib24","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.06.006_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13046-022-02340-2","article-title":"The role of tumor-infiltrating lymphocytes in cholangiocarcinoma","volume":"41","author":"Liu","year":"2022","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.06.006_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.872353","article-title":"The Prognostic Value of Natural Killer Cells and Their Receptors\/Ligands in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis","volume":"13","author":"Xue","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.006_bib27","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2024.06.006_bib28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/10408444.2020.1719974","article-title":"Toxicological profile of lipid-based nanostructures: are they considered as completely safe nanocarriers?","volume":"50","author":"Azarnezhad","year":"2020","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.ymthe.2024.06.006_bib29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s12276-022-00757-5","article-title":"RNA therapy: rich history, various applications and unlimited future prospects","volume":"54","author":"Kim","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ymthe.2024.06.006_bib30","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.18632\/oncotarget.23638","article-title":"YAP-associated chromosomal instability and cholangiocarcinoma in mice","volume":"9","author":"Rizvi","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2024.06.006_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abp9435","article-title":"Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases","volume":"8","author":"Wan","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2024.06.006_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/nano13202751","article-title":"Engineering Cell-Derived Nanovesicles for Targeted Immunomodulation","volume":"13","author":"Sayyed","year":"2023","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.ymthe.2024.06.006_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005112","article-title":"Cytofkit: A Bioconductor Package for an Integrated Mass Cytometry Data Analysis Pipeline","volume":"12","author":"Chen","year":"2016","journal-title":"Plos Comput. Biol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624003885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624003885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T02:52:02Z","timestamp":1763779922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624003885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1525001624003885"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.006","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}